Cargando…

Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives

The classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), which include polycythaemia vera, essential thrombocythaemia and primary myelofibrosis, originate from a stem cell-derived clonal myeloproliferation that manifests itself with variable haematopoietic cell lineage invol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vannucchi, Alessandro M, Guglielmelli, Paola, Rambaldi, Alessandro, Bogani, Costanza, Barbui, Tiziano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2009
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828857/ https://www.ncbi.nlm.nih.gov/pubmed/19522842 http://dx.doi.org/10.1111/j.1582-4934.2009.00827.x

Ejemplares similares

Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms
por: Guglielmelli, Paola, et al.
Publicado: (2010)

Chronic Myeloproliferative Neoplasms: a Collaborative Approach
por: Pieri, Lisa, et al.
Publicado: (2010)

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
por: Barbui, Tiziano, et al.
Publicado: (2018)

mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
por: Bogani, Costanza, et al.
Publicado: (2013)

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
por: Loscocco, Giuseppe G., et al.
Publicado: (2021)

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data
por: Loscocco, Giuseppe G, et al.
Publicado: (2020)

Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms: Friend and Enemy, Depending on Circumstances
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2023)

Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms
por: Barbui, Tiziano, et al.
Publicado: (2018)

An agenda for future research projects in polycythemia vera and essential thrombocythemia
por: Barbui, Tiziano, et al.
Publicado: (2020)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
por: De Stefano, Valerio, et al.
Publicado: (2018)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
por: Gianelli, Umberto, et al.
Publicado: (2022)

Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms
por: Bartalucci, Niccolò, et al.
Publicado: (2013)

Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper
por: Barbui, Tiziano, et al.
Publicado: (2019)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic
por: Barbui, Tiziano, et al.
Publicado: (2021)

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases
por: De Stefano, Valerio, et al.
Publicado: (2018)

Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018
por: Finazzi, Guido, et al.
Publicado: (2018)

Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment
por: Barbui, Tiziano, et al.
Publicado: (2022)

Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms
por: Tenedini, E, et al.
Publicado: (2014)

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
por: Lussana, Federico, et al.
Publicado: (2017)

Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms
por: Bochicchio, Maria Teresa, et al.
Publicado: (2022)

Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review
por: Malato, Alessandra, et al.
Publicado: (2020)

Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms
por: Sharma, Vasundhara, et al.
Publicado: (2020)

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
por: Shimizu, Takafumi, et al.
Publicado: (2016)

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value
por: Vannucchi, A M, et al.
Publicado: (2014)

Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms
por: Brkic, Sime, et al.
Publicado: (2020)

A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis
por: Carobbio, Alessandra, et al.
Publicado: (2020)

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms
por: Romano, Michela, et al.
Publicado: (2017)

High Frequency of Endothelial Colony Forming Cells Marks a Non-Active Myeloproliferative Neoplasm with High Risk of Splanchnic Vein Thrombosis
por: Rosti, Vittorio, et al.
Publicado: (2010)

The new WHO classification for essential thrombocythemia calls for revision of available evidences
por: Barbui, Tiziano, et al.
Publicado: (2020)

Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies
por: Mascarenhas, John, et al.
Publicado: (2011)

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives
por: Baumeister, Julian, et al.
Publicado: (2021)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4og453m231opfsn1rqpvtc1gbn